Lat­est news: Am­gen's land­mark OK for KRAS drug, in­side Ver­tex 3.0, the big hunt for CAR-T in sol­id tu­mors, and more

Last year
Weekly

Am­gen cracks the un­drug­gable code, earn­ing the FDA's nod for first-ever KRAS in­hibitor

Last year
Pharma
FDA+

Bris­tol My­ers gets its first GI drug ap­proval, and it comes from a long­time Cel­gene MS pro­gram

Last year
FDA+

FDA ad­comm votes in fa­vor of ap­prov­ing Proven­tion Bio’s drug to de­lay type 1 di­a­betes

Last year
Pharma
FDA+

Alise Re­icin re­cruits GNF vet Pe­ter Mc­Na­ma­ra to head re­search at Tim Springer's lat­est start­up

Last year
People
R&D

FDA steers J&J/Leg­end CAR-T to a quick de­ci­sion as part­ners prep a loom­ing show­down with Bris­tol My­ers, blue­bird

Last year
Cell/Gene Tx
FDA+

No­vo Hold­ings, Vi­vo lead a record $200M raise for a Sin­ga­pore-based tools play­er with plans for a Boston hub, new deals

Last year
Financing
China

FDA au­tho­rizes Vir-GSK an­ti­body as vari­ants threat­en Eli Lil­ly mAb

Last year
R&D
Coronavirus

Opin­ion: It shouldn’t mat­ter who the FDA com­mis­sion­er is when it comes to con­tro­ver­sial drug ap­proval de­ci­sions

Last year
FDA+
Opinion

Un­der-the-radar NiKang Ther­a­peu­tics bursts on­to the scene with $200M Se­ries C from in­vestors that screams IPO

Last year
Financing

Omid Farokhzad’s biotech in­sid­ers SPAC opens the deal win­dow with $200M to play with

Last year
Financing

Deaths of mon­keys spur clin­i­cal hold for rare dis­ease biotech's lead and on­ly drug — and a $95M cash in­fu­sion goes out the win­dow

Last year
FDA+

Black­stone en­lists a mur­der­ers' row of ad­vi­sors, in­clud­ing ex-Sanofi CEO Olivi­er Brandi­court, to steer life sci­ences biz

Last year
People
Financing

Pieris inks res­pi­ra­to­ry part­ner­ship with Genen­tech, adding an­oth­er to slate of mile­stone-heavy deals

Last year
Deals

The $70B ques­tion: What’s Pfiz­er go­ing to do with all that Covid vac­cine cash?

Last year
Deals
Bioregnum

Ab­b­Vie’s last stand: How an Ice­landic bil­lion­aire’s biosim­i­lar has one fi­nal shot to de­throne Hu­mi­ra

Last year
Pharma

Boehringer em­barks on a PhI­II odyssey for a failed Alzheimer's drug — now re­fo­cused on schiz­o­phre­nia with new tri­al tech and a ‘break­through’ at the FDA

Last year
R&D

Bi­par­ti­san House bill seeks new $30B ‘BioBonds’ loan pro­gram to rein­vig­o­rate clin­i­cal tri­als

Last year
Financing
R&D

NGM con­cedes key fail­ure for their lead NASH drug, clos­ing the door on a piv­otal fol­lowup — and ask­ing an­a­lysts to look past the wreck­age in­to the pipeline

Last year
R&D

Lat­est news on J&J’s NSCLC ap­proval, Bris­tol My­ers Squibb’s big TIG­IT bet, #AS­CO21 and more

Last year
Weekly

CVS splash­es in­to clin­i­cal tri­al ser­vices, lean­ing on lo­cal roots to change the game in terms of pa­tient en­gage­ment

Last year
Outsourcing

Arie Bellde­grun's vi­sion for Gink­go comes in­to view, as the now $15B com­pa­ny teams with Bio­gen on gene ther­a­py

Last year
Deals

No­var­tis' San­doz reshuf­fles an­tibi­ot­ic sup­ply chain in EU as field faces a short­age of in­vest­ment

Last year
Manufacturing

House com­mit­tee grills Emer­gent CEO Bob Kramer over J&J vac­cine de­ba­cle, ill-timed stock sale

Last year
People
R&D
First page Previous page 118119120121122123124 Next page Last page